In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.

In 2021, the FDA criticised MSD for relying on an early endpoint to seek approval for Keytruda in early-stage TNBC.

The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.

The approval for the KEYTRUDA regimen is supported by results from the Phase II/III IND.227/KEYNOTE-483 trial.

Summit shared data from the HARMONi-2 study at the World Conference on Lung Cancer conference in San Diego, US.

In its Phase 3 trial conducted in China, Ivonescimab shattered expectations, reducing the risk of disease progression or death by 49% compared to Merck’s Keytruda (pembrolizumab). With a nearly ...

The FDA approves subcutaneous formulation of RHHBY's leading immunotherapy drug, Tecentriq, under the brand name Tecentriq ...

Summit Therapeutics (NASDAQ: SMMT) recently reported Ivonescimab’s Phase 3 results from study conducted in China that showed significant efficacy in addressing NSCLC treatment ...

And certainly, our two key drivers have been KEYTRUDA and GARDASIL. And when I look at KEYTRUDA ... So really excited with sotatercept, WINREVAIR is its brand name. We received the approval. We're ...

"Our key data presentations highlight our scientific leadership in developing targeted therapies, including small molecules and antibody-drug conjugates ... ADC disitamab vedotin in combination with ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.